Teva Pharmaceutical/$TEVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Teva Pharmaceutical
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Ticker
$TEVA
Sector
Primary listing
NYSE
Employees
37,000
Headquarters
Tel Aviv, Israel
Website
TEVA Metrics
BasicAdvanced
$22B
-
-$0.14
0.60
-
Price and volume
Market cap
$22B
Beta
0.6
52-week high
$22.80
52-week low
$12.47
Average daily volume
11M
Financial strength
Current ratio
1.064
Quick ratio
0.483
Long term debt to equity
249.62
Total debt to equity
256.687
Interest coverage (TTM)
3.59%
Profitability
EBITDA (TTM)
4,522
Gross margin (TTM)
49.07%
Net profit margin (TTM)
-0.94%
Operating margin (TTM)
21.05%
Effective tax rate (TTM)
-138.24%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
5.65%
Return on equity (TTM)
-2.42%
Valuation
Price to revenue (TTM)
1.293
Price to book
3.17
Price to tangible book (TTM)
-1.63
Price to free cash flow (TTM)
24.154
Free cash flow yield (TTM)
4.14%
Free cash flow per share (TTM)
0.782
Growth
Revenue change (TTM)
2.07%
Earnings per share change (TTM)
-65.07%
3-year revenue growth (CAGR)
2.52%
10-year revenue growth (CAGR)
-1.91%
3-year earnings per share growth (CAGR)
-47.14%
10-year earnings per share growth (CAGR)
-26.26%
What the Analysts think about TEVA
Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.
Bulls say / Bears say
In Q2 2025, Teva reported adjusted EPS of $0.66, surpassing Wall Street estimates of $0.62, driven by a 26% rise in branded drug sales and prompting the company to raise its full-year Austedo, Ajovy, and Uzedy forecasts. (Reuters)
Teva’s Q1 2025 results outperformed forecasts with EPS of $0.52 versus $0.46 expected and revenue up 2% to $3.89 billion, underpinned by 39% growth in Austedo, 26% in Ajovy, and 156% in Uzedy. (Reuters)
As of Q1 2025, Teva reduced net debt to $15 billion and targets $700 million in net savings by 2027, strengthening its balance sheet and supporting future strategic initiatives. (Reuters)
Teva anticipates U.S. generic drug prices to erode by high single digits—worsening to around 7% through year-end 2025—reflecting intensifying pricing pressure from large pharmacy buyers. (Reuters)
Southwest Airlines filed an antitrust lawsuit in July 2025 alleging Teva participated in a price-fixing conspiracy that overcharged the airline for generic drugs, exposing the company to potential multibillion-dollar damages and reputational harm. (Reuters)
On July 8, 2025, the U.S. Court of Appeals upheld J&J’s patent for Invega Sustenna, blocking Teva’s generic entry into a market that generated over $4.2 billion in sales and underscoring headwinds in its specialty pipeline. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
TEVA Financial Performance
Revenues and expenses
TEVA Earnings Performance
Company profitability
TEVA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Teva Pharmaceutical stock?
Teva Pharmaceutical (TEVA) has a market cap of $22B as of September 16, 2025.
What is the P/E ratio for Teva Pharmaceutical stock?
The price to earnings (P/E) ratio for Teva Pharmaceutical (TEVA) stock is 0 as of September 16, 2025.
Does Teva Pharmaceutical stock pay dividends?
No, Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Teva Pharmaceutical dividend payment date?
Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Teva Pharmaceutical?
Teva Pharmaceutical (TEVA) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.